PsychedelicNewsBreaks

WednesdayOct 14, 2020 3:26 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Eyes Opportunity as Psilocybin Shows Promise for Treating Depression

Pure Extract Technologies, a private, plant-based extraction company, is positioned for opportunity as interest grows in the psychedelic and functional mushrooms sector. Recent groundbreaking research indicates that psilocybin-assisted psychotherapy may be effective in treating depression, a debilitating disorder that plagues an estimated 300 million people across the United States. According to a recent National Centre for Mental Health (“NCMH”) article, “a small number of studies have been conducted trialing psilocybin on patients with treatment-resistant depression.” Test results showed a significant decrease in depression scores after only one week to three months, with the majority of participants experiencing reduced depression severity…

Continue Reading

MondayOct 12, 2020 2:49 pm

PsychedelicNewsBreaks – Cybin Corp. Holds Distinct Strength in Psychedelics Space

Cybin Corp., a Canada-based, life-science company, is focused on the development of mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products. The company is positioning as countries around the world become increasingly accepting of psilocybin’s use in controlled settings and recent clinical studies unveil its potential in treating mental health disorders and other conditions. A recent article discussing the company’s pioneering efforts on this front reads, “Cybin already holds a unique strength in the psychedelics space. The company is responsible for some of the first published research on microdosing; i.e, the action or practice of taking or administering very small amounts of…

Continue Reading

ThursdayOct 08, 2020 1:24 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Positioning as Research Looks to the ‘Magic’ in Mushrooms

Pure Extract Technologies, a private, plant-based extraction company, is positioning for opportunity amid the ramping up of next-generation research regarding potential benefits of functional mushrooms and psilocybin compounds. The company is pursuing a Natural Health Products Site License from Health Canada to buy, sell and produce functional mushroom products in an EU-GMP-compliant environment. This will position Pure Extracts to partner with organizations that plan to develop both functional and psychedelic products. The timing appears optimal as further studies aim to explore the benefits of psychedelics, including potential anti-tumor effects, improved immune function, mental wellness, detoxification and more. A recent article…

Continue Reading

WednesdayOct 07, 2020 11:25 am

PsychedelicNewsBreaks – Rritual Mushrooms Inc. Engages InvestorBrandNetwork

Rritual Mushrooms, a premium brand in the emerging functional mushroom market, has announced that it has selected InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, for its communication needs. Founded in 2019, Rritual Mushrooms is a private company with a declared purpose to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets. Rritual Mushrooms engaged IBN to leverage its investor-based distribution network of more than 5,000 key syndication outlets, social media channels, wire services and more to tell the Rritual story. That story includes Rritual’s ability to…

Continue Reading

MondayOct 05, 2020 10:54 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Elects Leading International Expert as Board Chairman

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today announced the election of Dr. Roger McIntyre as chairman of its board of directors. A foremost international expert in depression and suicide, Dr. McIntyre is a professor of Psychiatry and Pharmacology at the University of Toronto, heads the Mood Disorders Unit at the University Health Network in Toronto and holds appointments among scientific and clinical organizations across the United States and Asia. Dr. McIntyre was appointed to Champignon’s board in July 2020 and assumed the role of CEO in May 2020. He has set a strategic direction for the business, which…

Continue Reading

FridayOct 02, 2020 1:28 pm

PsychedelicNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion

Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings more than three decades of experience and a recognition of psychedelics as a major breakthrough in treating mental health conditions. Amid the recent strong push for research and commercialization in the psychedelics sector, Drysdale seeks to pursue emerging opportunities and pave the road for the company’s rapid growth. “I am beyond excited to be joining the Cybin team,” Drysdale stated in a recent article of…

Continue Reading

FridaySep 25, 2020 2:07 pm

PsychedelicNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed…

Continue Reading

ThursdaySep 24, 2020 3:51 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Eyes Functional Mushroom Sector for Initial Product Lines

Pure Extract Technologies, a private, plant-based extraction company poised to enter the commercial cannabis sector with a new vertical in functional mushrooms, has seized the opportunity to reveal its business development strategy (https://ibn.fm/6OXiR). A recent article discussing this reads, “As Pure Extracts positions itself to become the premier commercialization and manufacturing partner for functional companies going forward, the company plans to center its initial product lines on functional mushroom products. In its bid to do so, the company is applying for a Natural Health Products site license with Health Canada, which, once received, will enable Pure Extracts to begin producing clinical…

Continue Reading

FridaySep 18, 2020 1:36 pm

PsychedelicNewsBreaks – Pure Extract Technologies Inc. Poised as ‘Psychedelic Events Are Going Mainstream’

Pure Extract Technologies, a private, plant-based extraction company, is well positioned to partner with organizations eyeing development in both functional and psychedelic products. The company’s entry into functional medicinal mushrooms and collaboration in the psychedelic space look to be appropriately timed for a sector experiencing rising popularity and growing investment. An article discussing this highlights excerpts from a recent “Forbes” publication, titled “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health” (http://ibn.fm/10yfG). The piece reads, “Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades. In 2020, whether consuming, investing, or…

Continue Reading

TuesdaySep 15, 2020 3:06 pm

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Update Regarding Ongoing Disclosure Review

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) continues to work with the British Columbia Securities Commission to address an ongoing continuous disclosure review. According to the update, the company has arranged for the following since the review commenced: Filing of business acquisition reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.; revocation of the initial cease trade order issued by the Commission on June 19, 2020; preparation of financial disclosure in connection with the acquisition of AltMed Capital Corp. (“AltMed”). The company expects this work to be concluded shortly, as…

Continue Reading